Haws Brittany E, Khechen Benjamin, Patel Dil V, Yoo Joon S, Guntin Jordan A, Cardinal Kaitlyn L, Ahn Junyoung, Singh Kern
Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL, USA.
Neurospine. 2019 Dec;16(4):772-779. doi: 10.14245/ns.1938006.003. Epub 2019 Jul 8.
The relationship between bone graft technique and postoperative outcomes for minimally invasive transforaminal lumbar interbody fusion (MIS TLIF) has not been well-defined. This study aims to determine the effect of iliac crest bone grafting (ICBG) on patient-reported outcomes (PROs) and complication rates following MIS TLIF.
Primary, single-level MIS TLIF patients were consecutively analyzed. Patients that prospectively received a percutaneous technique of ICBG were compared to patients that retrospectively received bone morphogenetic protein-2 (BMP-2). Complication rates were assessed perioperatively and up to 1 year postoperatively. Changes in Oswestry Disability Index (ODI), visual analogue scale (VAS) back, and VAS leg pain were compared. Rates of minimum clinically important difference (MCID) achievement at final follow-up for ODI, VAS back, and VAS leg scores were compared.
One hundred forty-nine patients were included: 101 in the BMP-2 cohort and 48 in the ICBG cohort. The ICBG cohort demonstrated increases in intraoperative blood loss and shorter lengths of stay. ICBG patients also experienced longer operative times, though this did not reach statistical significance. No significant differences in complication or reoperation rates were identified. The ICBG cohort demonstrated greater improvements in VAS leg pain at 6-week and 12-week follow-up. No other significant differences in PROs or MCID achievement rates were identified.
Patients undergoing MIS TLIF with ICBG experienced clinically insignificant increases in intraoperative blood loss and did not experience increases in postoperative pain or disability. Complication and reoperation rates were similar between groups. These results suggest that ICBG is a safe option for MIS TLIF.
微创经椎间孔腰椎椎体间融合术(MIS TLIF)中骨移植技术与术后疗效之间的关系尚未明确界定。本研究旨在确定髂嵴骨移植(ICBG)对MIS TLIF术后患者报告结局(PROs)及并发症发生率的影响。
对接受初次单节段MIS TLIF的患者进行连续分析。将前瞻性接受经皮ICBG技术的患者与回顾性接受骨形态发生蛋白-2(BMP-2)的患者进行比较。在围手术期及术后1年内评估并发症发生率。比较Oswestry功能障碍指数(ODI)、视觉模拟量表(VAS)背痛评分及VAS腿痛评分的变化。比较末次随访时ODI、VAS背痛评分及VAS腿痛评分达到最小临床重要差异(MCID)的比例。
共纳入149例患者:BMP-2组101例,ICBG组48例。ICBG组术中失血量增加,住院时间缩短。ICBG组患者手术时间也较长,尽管未达到统计学意义。未发现并发症或再次手术率有显著差异。ICBG组在术后6周和12周时VAS腿痛评分改善更明显。未发现PROs或MCID达成率有其他显著差异。
接受ICBG的MIS TLIF患者术中失血量虽有临床意义不显著的增加,但术后疼痛或功能障碍并未增加。两组间并发症和再次手术率相似。这些结果表明,ICBG是MIS TLIF的一种安全选择。